Food and Drug Administration Procedures for New Drug and Device Approvals

Affiliations

¹ Ocular Inflammatory Disease Center, UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: uveitis@jsei.ucla.edu.
² Division of Ophthalmic and Ear, Nose, and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
³ Division of Transplant & Ophthalmology Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

Editorial

Gary N Holland et al. Am J Ophthalmol. 2016 Jan.

. 2016 Jan:161:1-3.

doi: 10.1016/j.ajo.2015.11.022.

¹ Ocular Inflammatory Disease Center, UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: uveitis@jsei.ucla.edu.
² Division of Ophthalmic and Ear, Nose, and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
³ Division of Transplant & Ophthalmology Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy.
Zarranz-Ventura J, Keane PA, Sim DA, Llorens V, Tufail A, Sadda SR, Dick AD, Lee RW, Pavesio C, Denniston AK, Adan A; EQUATOR Study Group. Zarranz-Ventura J, et al. Am J Ophthalmol. 2016 Jan;161:172-80.e1-4. doi: 10.1016/j.ajo.2015.10.009. Epub 2015 Oct 23. Am J Ophthalmol. 2016. PMID: 26476212